Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2Multiple Myeloma 2Ovarian Neoplasms 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Fallopian Tube Neoplasms 1Disease Progression 1Disease 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 8Oxaliplatin 6Irinotecan 6Leucovorin 5Cisplatin 5Radiotherapy 4Fluorouracil 4Capecitabine 4pembrolizumab 3Interleukin-12 Subunit p35 3Erlotinib Hydrochloride 3Trastuzumab 2Carboplatin 2tipifarnib 1spartalizumab 1ricolinostat 1motexafin gadolinium 1irinotecan sucrosofate 1entinostat 1dehydroftorafur 1Thalidomide 1Protein Subunit Vaccines 1Positron Emission Tomography Computed Tomography 1Polymerase Chain Reaction 1Platinum 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Microarray Analysis 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Bile Duct Neoplasms × ricolinostat × Clear all
NCT02856568 2017-05-30

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡